Download Full eBooks in PDF
A Guide To Biotechnology Finance Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of A Guide To Biotechnology Finance book. This book definitely worth reading, it is an incredibly well-written.
Author : Minnesota. Department of Employment and Economic Development,Lindquist & Vennum
Publisher : Minnesota Department of Employment and Economic Development
Page : 260 pages
File Size : 54,6 Mb
Release : 2005
Category : Biotechnology
ISBN : MINN:31951D02407191F
Author : Bryan Bergeron,Paul Chan
Publisher : John Wiley & Sons
Page : 384 pages
File Size : 40,9 Mb
Release : 2004-04-12
Category : Business & Economics
ISBN : 9780471647577
"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
Author : Karl Keegan
Publisher : John Wiley & Sons
Page : 216 pages
File Size : 50,8 Mb
Release : 2009-01-15
Category : Business & Economics
ISBN : 9780470741344
The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." —Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." —Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company
Author : Joe Duarte
Publisher : Prima Lifestyles
Page : 424 pages
File Size : 47,5 Mb
Release : 2001
Category : Business & Economics
ISBN : IND:30000078411265
Medical biotechnology is a multibillion dollar global industry, and is growing rapidly. Breakout companies worldwide present highly profitable investment opportunities, but many investors avoid the sector because the science is difficult to understand and the opportunities easy to miss. Where can the layperson find reliable, fundamental information about biotechnology in order to make informed investment decisions?In Successful Biotech Investing, market expert and physician Joe Duarte, M.D., makes investing in biotech companies -- and understanding the basic science -- easy. He combines his professional medical insight and extensive financial experience to help investors easily master how to: * Interpret the science to make informed investment decisions* Analyze biotech companies for research, patents, and growth potential* Pick biotech mutual funds and indexes for maximum profit* Identify related opportunities in pharmaceutical and health-care companies* Understand the impact of the FDA and international regulations* And much moreWritten for smart investors who want to learn more about biotech and its opportun
Author : Tang Mark Chilung
Publisher : World Scientific
Page : 282 pages
File Size : 47,8 Mb
Release : 2002-12-02
Category : Business & Economics
ISBN : 9789814487641
This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Author : Craig Shimasaki
Publisher : Academic Press
Page : 489 pages
File Size : 48,8 Mb
Release : 2014-04-08
Category : Medical
ISBN : 9780124047471
As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a ‘how-to’ for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars Case studies are interspersed throughout each chapter to support key concepts and best practices. Enhanced by use of numerous detailed graphics, tables and flow charts
Author : Chilung Mark Tang
Publisher : Turtleback
Page : 128 pages
File Size : 55,6 Mb
Release : 2002-08-01
Category : Business & Economics
ISBN : 0613918673
This invaluable book tells the reader how to invest in the healthcare biotechnology and life science sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Author : Donald L. Drakeman,Lisa N. Drakeman,Nektarios Oraiopoulos
Publisher : Oxford University Press
Page : 241 pages
File Size : 54,8 Mb
Release : 2022
Category : Biotechnology industries
ISBN : 9780195084009
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Author : Dimitrios Iliopoulos
Publisher : Createspace Independent Publishing Platform
Page : 214 pages
File Size : 42,9 Mb
Release : 2016-11-01
Category : Electronic
ISBN : 1539874389
Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech start-ups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than $9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising $450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, including novel financial models used for valuation of biotech companies. Furthermore, we have created new biotech valuation cases providing to the reader a practical guide for valuation of any biotech product or company.
Author : Carole Moussalli
Publisher : Vault Inc.
Page : 184 pages
File Size : 50,9 Mb
Release : 2004
Category : Bioengineering
ISBN : 9781581312683
Vault brings its award-winning career information process to this important and booming industry, with information on career paths for both the science and business (sales, marketing, etc.) sides.
Author : Dimitris Dogramatzis
Publisher : CRC Press
Page : 690 pages
File Size : 48,7 Mb
Release : 2016-04-19
Category : Business & Economics
ISBN : 9781439894125
Foreseeing and planning for all of the possibilities and pitfalls involved in bringing a biotechnology innovation from inception to widespread therapeutic use takes strong managerial skills and a solid grounding in biopharmaceutical research and development procedures. Unfortunately there has been a dearth of resources for this aspect of the field.
Author : Andrew Craig
Publisher : Nicholas Brealey
Page : 0 pages
File Size : 47,7 Mb
Release : 2024-09-03
Category : Science
ISBN : 9781399800358
Welcome to the biotech revolution In the last century, technology has transformed the human experience across the world. This has been super-charged by the arrival of the internet, smart phones, AI and machine learning, and created trillion-plus dollar companies and household names like Apple, Amazon, Google and Microsoft. Our Future is Biotech explains why biotech is next: because our biggest remaining challenges as a species concern biological systems. Biotech companies will solve our most intractable problems, from cancer, dementia, obesity and diabetes to elderly care, mental health conditions, and even power generation, agricultural production and environmental degradation. Biotech means that we will live better, safer, healthier, wealthier, happier, and longer lives. The industry has already delivered "miracle cures" for several diseases, and there is more to come. But despite this, few people are aware of the phenomenal progress being made. Our Future is Biotech addresses this, explaining what biotech is, what is coming next, and how you might profit from it too. Tech has been the most important theme for human progress for the last century. Biotech is next.
Author : Boris Bogdan,Ralph Villiger
Publisher : Springer Science & Business Media
Page : 257 pages
File Size : 45,5 Mb
Release : 2007-03-23
Category : Business & Economics
ISBN : 9783540455677
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. It introduces the characteristics of drug and medical device development, explains how to translate these into the valuation, and provides valuable industry data. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
Author : M O'Neill,M M Hopkins
Publisher : Elsevier
Page : 414 pages
File Size : 55,5 Mb
Release : 2012-05-02
Category : Business & Economics
ISBN : 9781908818157
A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur. No other 'how to' manual exists for this sector Written by a range of expert professionals in each area, all in one book Is the only 'bench to bedside' book covering the whole spectrum of development
Author : Standard and Poor's Corporation
Publisher : McGraw Hill Professional
Page : 336 pages
File Size : 55,9 Mb
Release : 2003
Category : Biotechnology industries
ISBN : 0071384138
Standard and Poor's has been the leading brand in financial information and analysis around the world. Brokers, investment bankers, and other Wall Street professionals have relied upon S&P's unparalleled financial analysis for over 140 years. Their stock reports and ratings are among the most-respected in the industry. Now S&P's celebrated stock reports are collected for the top-rated stocks in the S&P 1500 composite index for each of today's five hottest stock sectors. Finance; Technology; Health Care, Pharmaceutical and Biotechnology; Energy; Communications and Telecom; The industries in these sectors include some of the fastest growing stocks around, and each of them include stocks assigned the prestigious 5-Star rating by S&P's top analysts. 65 percent of the 5-Star rankings allotted to stocks in S&P's 1500 composite index were assigned to stocks in one these 5 sectors! Included in each book are S&P's exclusive stock reports for the top-rated companies in each industry in the sector. Each book will also contain S&P analysts' valuable analysis of the sector as a whole and exclusive advice on how to evaluate stocks in each industry in the sector.